Ignite Creation Date:
2024-05-06 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 2:50 PM
Study NCT ID:
NCT05713279
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-09-26
First Post:
2023-01-17
Brief Title:
Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus COVID-19 Infection
Sponsor:
Chengdu Zenitar Biomedical Technology Co Ltd
Organization:
Chengdu Zenitar Biomedical Technology Co Ltd
Study Overview
Official Title:
Preliminary Clinical Study of Efficacy and Safety of Flunotinib Maleate Tablets Combined With Antiviral Therapy in Patients With Severe Novel Coronavirus COVID-19 Infection
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Flonoltinib Maleate as a JAKFLT3 dual target inhibitor previous pharmacological experiments showed that the IC50 inhibition of JAK2 kinase was as low as 08 nM while the IC50 inhibition of JAK1 JAK3 and TYK2 kinases was 26 nM 39 nM and 2 nM respectively and the IC50 of FLT3 kinase was 15 nM It has high inhibitory activity for JAK2 kinase and good selectivity for JAK familyMultiple pharmacodynamic models evaluating the anti-inflammatory effect of Flonoltinib Maleate showed that Flonoltinib Maleate showed better therapeutic effect than the clinical drug Ruxolitinib with lower toxicity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None